Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 April 2020 | Story Department of Communication and Marketing | Photo Charl Devenish
Farmovs
In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.

The University of the Free State (UFS) is committed to supporting government’s efforts to overcome the COVID-19 pandemic. During this challenging time, dedicated staff members at the UFS continue to provide services as a testimony to their commitment to advance public knowledge of COVID-19 for the greater good of South Africa.

The following is a synopsis of the areas in which the UFS is actively assisting.

Public Health Emergency Solidarity Trial
Clinicians from the Department of Internal Medicine, the Department of Critical Care, and the Division of Virology will be working with FARMOVS to participate in the Public Health Emergency Solidarity Trial initiated by the World Health Organization (WHO). This international randomised trial will evaluate four treatment options (remdesivir, lopinavir/ritonavir, lopinavir/ritonavir plus interferon, chloroquine or hydroxychloroquine) for the treatment of COVID-19. 

The trial is expected to include more than 45 countries worldwide, including a number of South African sites. 

Farmovs

FARMOVS is in a planning process to support all the Bloemfontein hospitals, including Pelonomi, Universitas, 3 Military Hospital, Mediclinic, and Rosepark, in conducting the largest global trial on COVID-19 – the Public Health Emergency Solidarity Trial, under leadership of the WHO.   

Negotiations are ongoing between the UFS and the Department of Health in the Free State for FARMOVS to offer support with the continuation of healthcare to non-COVID-19 patients in an attempt to free up space at Universitas Hospital for isolation of COVID-19 patients. 

In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.  FARMOVS also receives feasibility requests for support with the evaluation of existing drugs (repurposing) as well as the development of novel drugs for the treatment of COVID-19 – this is an ongoing process.

Disaster Management Training and Education Centre (DiMTEC)
DiMTEC represents the UFS on the Provincial Joint Operation Centre (PROVJOC). The PROVJOC is a fully equipped, dedicated facility that is proactively established to enable all relevant role players /disciplines to jointly manage all safety and security-related aspects of any planned event or any major incident which has occurred or is imminent – especially in the response and recovery operations phase – at the strategic and/or tactical level, using the Unified Command System. This facility is also linked to all other established safety and security centres.

Research and Innovation
The UFS hosts a SARChI Research Chair in vector-borne and zoonotic diseases, and recently invested in the establishment of a biosafety level-3 facility. Hence, there is expertise on the campus to plan and conduct research on zoonotic and medically significant viruses. In addition, there are research groups focusing on protein expression systems with potential for utilisation in the development of diagnostic assays with application in either diagnosis or surveillance.

Currently, researchers at the UFS have established several projects that will contribute directly towards the COVID-19 outbreak.


News Archive

University is proud of its women in science
2013-08-17

 

Dr Marieka Gryzenhout
Photo: Sonia Small
19 August 2013

Two lecturers in the Department of Plant Sciences received national recognition for their research at the Women in Science Award 2013 function of the Department of Science and Technology (DST) on Friday 16 August 2013. Dr Marieka Gryzenhout received the award as Young Women Scientist and Prof Maryke Labuschagne was first runner-up in the category Distinguished Women Researcher, both in Life Sciences.

The third award-winner was Rose Lekhooa in the Doctoral Fellowship category. She is studying toward a PhD in Pharmacology and said the fellowship will enable her to attend seminars and workshops internationally.

Friday’s award was the second, in as many months, for Dr Gryzenhout. She received the TW Kambule NRF-NSTF Award as emerging researcher in June 2013. She was the recipient of the International Union of Forestry Research Organizations’ Outstanding Doctoral Research award in 2010.

Prof Jonathan Jansen, Vice-Chancellor and Rector of the UFS, said, “Dr Gryzenhout represents one of a growing group of very impressive young scientists at the university who are emerging as leading international scholars in their fields.

“Her international leadership in mycology research has already made significant impacts on the African continent and beyond. The university will continue to invest in these young academic stars through its Prestige Scholars Programme where scholars like Dr Gryzenhout are increasingly well-placed to be the next generation of scientific leaders in the world.”

“It as a great privilege to receive the award, especially as second one in this year,” Dr Gryzenhout said. She established a research programme, Mycotoxigenic and Phytopathogenic Fungi, at the UFS. She is president of the African Mycological Association and general secretary of the International Society for Fungal Conservation. She is also a member of the Nomenclature Committee for Fungi – a permanent committee of the International Botanical Congress.

Prof Labuschagne received the African Union Kwame Nkrumah award for life and earth sciences in 2011, and the National Agriculturalist of the Year Award and the National Science and Technology Forum (NSTF) Award for research-capacity development over the last five to ten years, both in 2008.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept